Difference between revisions of "Immune effector cells toxicity management"
Jump to navigation
Jump to search
m |
m (→Guidelines) |
||
Line 19: | Line 19: | ||
==EBMT/JACIE/EHA== | ==EBMT/JACIE/EHA== | ||
*'''2022:''' Hayden et al. [https://doi.org/10.1016/j.annonc.2021.12.003 Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)] | *'''2022:''' Hayden et al. [https://doi.org/10.1016/j.annonc.2021.12.003 Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)] | ||
+ | ==SITC== | ||
+ | *'''2020:''' Maus et al. [http://dx.doi.org/10.1136/jitc-2020-001511 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events] | ||
=REMS programs= | =REMS programs= |
Revision as of 13:18, 17 February 2023
Page co-editor | Page co-editor | ||
---|---|---|---|
Leyre Zubiri, MD, PhD Massachusetts General Hospital Boston, MA |
Matthew Hadfield, DO Lifespan/Brown University Providence, RI |
The purpose of this page is to address the management of toxicity from BiTE and immune effector cell (IEC) therapy, notably CAR-T. There is a separate page for the management of immune checkpoint inhibitor (ICI) toxicities, available here.
Guidelines
ASCO
- 2021: Santomasso et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
ASTCT
- 2019: Lee et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
EBMT/JACIE/EHA
SITC
- 2020: Maus et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events